Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Down 45.3% in December

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a large decline in short interest in December. As of December 15th, there was short interest totaling 11,067 shares, a decline of 45.3% from the November 30th total of 20,224 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily volume of 33,204 shares, the short-interest ratio is presently 0.3 days. Based on an average daily volume of 33,204 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the company’s stock are sold short.

Matinas Biopharma Stock Performance

NYSEAMERICAN:MTNB opened at $0.62 on Friday. The firm has a market cap of $3.97 million, a P/E ratio of -0.18 and a beta of 1.32. Matinas Biopharma has a fifty-two week low of $0.47 and a fifty-two week high of $3.09. The firm has a 50-day simple moving average of $1.02 and a two-hundred day simple moving average of $1.27.

Matinas Biopharma (NYSEAMERICAN:MTNB) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical?stage biopharmaceutical company that specializes in the development of novel lipid?based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water?soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life?threatening fungal infections.